Literature DB >> 27855437

The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?

Hans-Jürgen Möller1.   

Abstract

Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. They are often persistent and tend to chronicity. They have an important negative impact on different dimensions of outcome and therefore require careful diagnosis and treatment. However, the evidence for the available psychopharmacological treatments is still not satisfactory and further research is needed. Antipsychotics, especially some second-generation antipsychotics, are the primary treatment of choice, particularly for negative symptoms in the acute episode. In case of residual negative symptoms concomitant treatment with antidepressants is often indicated. Glutamatergic compounds are of great theoretical interest as an add-on treatment or even as a monotherapy, but so far the efficacy results are inconsistent and their clinical use is limited.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27855437

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  5 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 2.  Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.

Authors:  Amber Edinoff; Miriam T Ruoff; Yahya T Ghaffar; Arthur Rezayev; Devanshi Jani; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14

3.  Functional Impairments and Theory of Mind Deficits in Schizophrenia: A Meta-analysis of the Associations.

Authors:  Élisabeth Thibaudeau; Caroline Cellard; Mélissa Turcotte; Amélie M Achim
Journal:  Schizophr Bull       Date:  2021-04-29       Impact factor: 9.306

4.  Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial.

Authors:  Jingmei Xiao; Jing Huang; Yujun Long; Xiaoyi Wang; Ying Wang; Ye Yang; Gangrui Hei; Mengxi Sun; Jin Zhao; Li Li; Tiannan Shao; Weiyan Wang; Dongyu Kang; Chenchen Liu; Peng Xie; Yuyan Huang; Renrong Wu; Jingping Zhao
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

Review 5.  Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.

Authors:  Amber N Edinoff; Natalie W Wu; Benjamin S Maxey; Amy L Ren; Kenna N Leethy; Brook Girma; Amira Odisho; Jessica S Kaye; Aaron J Kaye; Adam M Kaye; Alan D Kaye; George Mychaskiw; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.